AML in elderly. D.Selleslag AZ Sint-Jan Brugge, Belgium 14 December 2013
|
|
- Elisabeth Carter
- 5 years ago
- Views:
Transcription
1 AML in elderly D.Selleslag AZ Sint-Jan Brugge, Belgium 14 December 2013
2 AML is predominantly a disease of the elderly incidence 2 3/ SEER Cancer Statistics, National Cancer Institute, USA Available at
3 AML in the elderly is associated with poor survival rates SEER Cancer Statistics, National Cancer Institute, USA Available at
4 Poor treatment tolerance Resistant disease
5 Host factors in elderly AML
6 Elderly population is heterogeneous There is no uniform definition of fitness Fitness is a subjective impresssion Choice of therapy is subjective: physician dependent
7 In clinical practice we use performance score to define fitness
8
9 Performance score is more important than age for prediction of day 30 induction mortality r age < 56 yr yr yr > 75 yr PS 0 2 % 11 % 12 % 14 % PS 1 3 % 5 % 16 % 18 % PS 2 2 % 18 % 31 % 50 % PS 3 0 % 29 % 47 % 82 % % PS % 24 % 26 % 32 % Appelbaum et al, Blood, 2006
10 Performance score has limitations Does not differentiate between physical impairment due to Leukemia (reversible with therapy) Comorbidity unrelated to leukemia (irreversible) May fluctuate during diagnostic work up More objective parameters to define fitness are required and should be prospectively validated - geriatric assessment scales - comorbidity scores
11 Treatment of elderly AML
12 Treatment choice and treatment goals are not the same for all elderly AML Treatment intensity Improve QoL Prolong survival Cure Disease biology POOR GOOD Host factors UNFIT FIT
13 Standard treatment options for elderly AML Supportive / palliative are CR 0 % Med OS 2 mts, OS 5 yrs 0 % Low dose Ara C CR %, ED 25 % Med OS 4 mts, OS 5 yrs 0 % Not efficient with unfavourable karyotypes Intensive chemotherapy (3 + 7 induction) CR %, ED % Med OS 10 mts, OS 5 yrs < 15 % Little effect with adverse karyotype
14 LDAC is associated with poor survival in patients with unfavourable cytogenetics AML14 trial comparing LDAC vs HU in patients unfit for intensive treatment LDAC does not provide a survival benefit versus HU in patients with adverse cytogenetics who are ineligible for intensive treatment Burnett AK, et al. Cancer 2007;109:
15 Intensive approach Age, y CR % ED % Cure % < < > < 15
16 Intensive chemotherapy is associated with poor survival in patients with AML aged >60 years Survival is particularly poor in patients with abnormal cytogenetic profiles Knipp S, et al. Cancer 2007;110:345 52
17 Do we have data supporting the choice for intensive or non intensive approach? Limited data EORTC study (1989 )in 60 pts randomized between IC and supportive care We need a large randomized study but the the MRC AML14 study showed that only 8 of 1485 pts were randomized (patient or physician decision)
18 Intensive induction vs supportive care in elderly AML Intensive chemotherapy Palliative therapy Complete remission 58 % 0 % Early death 3/31 18/29 Median survival 21 weeks 11 weeks Survival at 2,5 yrs 17 % 0 % % of days in hospital Lowenberg et al, JCO, 1989 ; 7, 1268
19 How many patients can be treated with IC? Kantarjian, Blood 2010, 116: 4422 Number adverse factors N (%) of patients Mortality Week 8 (%) CR (%) (28%) (40%) Do (23%) not treat 55 intensively or more 38 (9%) MDACC Risk factors Age > = 80 PS = 2 4 Complex karyotype (3 or more abn) Creatinine > 1.3 mg/dl Survival at 2 yrs
20 Intensive chemotherapy: induction What do we know from randomized studies? Standard: with Dauno mg/m2 x 3 AraC mg/m2 CI x yrs: Dauno 90 mg/m2 x 3 : better OS No improvement of OS with addition of 6TG, etoposide new anthracyclins
21 Intensive therapy: post remission What do we know from randomized studies? 1. Consolidation : Consolidation vs no consolidation: never tested (all RCT use some form of consolidation) High vs conventional dose AraC : no advantage Multiple (4 vs 1, 4 vs 3) consolidations : no advantage 2. Maintenance: LD AraC improves remission duration, but not survival
22 EORTC/HOVON AML-9: DFS from 2 nd Randomization Lowenberg, JCO, No AraC LD AraC Logrank P = (years) O N Number of patients at risk : April 99 Induction Consolidation Maintenance R: LD Ara vs no LD AraC No AraC AraC
23 EORTC- HOVON AML-9: OS from 2 nd Randomization April LD AraC Logrank P = No AraC 0 (years) O N Number of patients at risk : No AraC AraC
24 Relapse Non relapse mortality Leukemia free survival Overall survival Farag et al, BBMT 2011
25
26
27 Can we wait for the karyotype? Delay of chemotherapy (< 5 vs > 5 days) does not influence survival in AML > 60 yrs and WBC < /mm3 Sekeres, M. A. et al. Blood 2009;113:28 36
28 Investigational therapies for elderly AML
29 New agents Hypomethylating agents Azacytidine Decitabine Clofarabine Gemtuzumab Flt3 inhibitors Quizartinib Volasertib CPX351..
30 Clofarabine is a Purine Nucleoside analogue N NH 2 N N NH 2 N N NH 2 N N NH 2 N HO N O N Cl HO N O N F HO N O HO N Cl HO N O F N HO HO deoxyadenosine cladribine HO HO fludarabine clofarabine Clofarabine: registered for relapsed ALL < 21 yrs
31 Clofarabine (Genzyme, Sanofi) Very active as monotherapy in AML Relapsed AML: CR 50 % Dose: 40 mg/m2 x 5 days Elderly AML not eligible for IC: CR 45 %, OS 1 yr for CR pts Dose : 30 (20) mg/m2 x 5 days (Kantarjian, Burnett, JCO 2010) High CR also in unfavourable cytogenetics Disappointing results in randomized studies: Will clofarabine ever be commercialized?
32 Burnett et al, ASH 2012
33 Burnett et al, ASH 2012
34 DNA hypermethylation is reversible Normal M M M Hypomethylating agents Expressed DNA methyl transferase M M M M M M M M M Cancer MDS Silencing of regulatory genes (e.g. tumor suppressor genes) Courtesy of Issa, JP
35 Hypomethylating Cytosine Analogs NH 2 NH 2 NH 2 NH 2 N CH 3 N CH 3 CH 3 N N N N N O N O N O N O Ribose Deoxyribose Cytosine 5-methyl-cytosine 5-aza-cytidine 5-aza-2 -deoxycytidine (azacitidine) (decitabine) Vidaza (Celgene) Dacogen (J&J) FDA /EMA approved FDA/EMA approved
36 Interphase = G1 +S + G2 S G1 G2 M
37 AZA 001: phase III survival study Treatment continued until relapse, unacceptable adverse events, disease progression MDS Int2 High (n = 358) Randomization AZA 75 mg/m 2 /day SC for 7 days every 28 days (n = 179) Investigator selection of Conventional Care Regimens Convential care regimens (n = 179) Best supportive care only Low dose cytarabine (20 mg/m 2 /day for 14 days every days) Standard chemotherapy (7 + 3) Fenaux P, et al. Lancet Oncol. 2009;10:
38 AZA-001 post hoc analysis: OS in pts with 20 30% blasts (WHO AML) Patients surviving (%) months 24.5 months Azacitidine (n=55) CCR (n=58) 0 p = Time from randomisation (months) Fenaux P, et al. Poster presentation at ASH 2008, San Francisco, CA, USA 38
39 AZA-001: OS in patients who achieved HI as best response 100 Azacitidine CCR Patients surviving (%) months Median not reached CR is not required for survival benefit 0 0 p< Time from randomisation (months) List AF, et al. Oral presentation at ASCO 2008, Chicago, IL, USA 39
40 Vidaza EU Label 2008 Vidaza is indicated for: Int-2 / High-risk MDS (IPSS) CMML with 10 29% marrow blasts without MPD WHO-classified AML with 20 30% blasts and multilineage dysplasia not eligible for HSCT So far no approval for AML > 30 % blasts 40
41 AML- AZA 001(Celgene) Stratification Based on cytogenetics
42 Decitabine vs Treatment of Choice in elderly AML (DACO-016) N = 485 CR + CRp 17.8 % vs 7.8 % p = No difference in safety Kantarjian et al. J Clin Oncol. 2012; 30(21):
43 OS Protocol-specified 2009 clinical cutoff analysis (396 deaths) Kantarjian et al. J Clin Oncol. 2012; 30(21):
44 OS Ad hoc mature (2010) analysis (446 deaths) Significant Survival Benefit for decitabine Kantarjian et al. J Clin Oncol. 2012; 30(21):
45 DACOGEN (decitabine) : EU label Adult patients 65 years Newly diagnosed de novo or secondary AML according to WHO classification (> 20% blasts) Not candidate for standard induction chemotherapy EU registration since September 2012 No FDA approval for AML Belgian reimbursement since 1 December 2013 PS 2 or more Significant comorbidities (HCT-CI) Secondary AML Poor cytogenetics or molecular features Stop if no response after 4 cycles 45 45
46
47 Human Mouse
48 Gemtuzumab Relapsed or refractory AML CR = 25 %, remission duration 6 mths Side effects Hepatotoxicity, Myelosuppression No mucositis, no alopecia, no cardiotoxicity Elderly AML Postconsolidation: no improvement of survival in elderly AML with 3 doses GO 6 mg/m2 (Blood, 2010, HOVON) Unfit elderly: Low dose AraC +/ GO: more CR, but no survival benefit (Burnett, Leukemia, 2013) Fit elderly: Intensive chemo +/ GO
49 1 Castaigne et al, Lancet 2012; 2 Burnett et al, JCO 2012; 3 Amadori et al, JCO 2013 (in press)
50 Quizartinib (Astellas, Ambit)
51 Quizartinib: efficacy > 60 yrs, refractory to or relapsed < 1 year after first line CT (Martinelli, ASCO 2013) Flt3 ITD + (110) Flt3 ITD (44) CRc = CR + Cri + CRp 57 % 36 % HSCT 10 % 2 % Median CRc 12.1 wks 10.8 wks duration Median OS 25.3 wks 19.1 wks Survival > 12 mths 15 % 14 %
52 Quizartinib : next step: phase III
53 Polo like Kinase 1: key regulator of mitosis and interesting target for treatment Prometaphase Spindle Assembly Metaphase Centrosome Maturation Mitotic exit Prophase Plk1 Anaphase Mitotic entry Interphase Telophase CytoKinesis
54 Volasertib phase II study (Boehringer)
55 Maertens et al, ASH 2012
56 Kantarjian et al, Lancet Oncol 2012; Cortes et al, Lancet Oncol 2013; Stuart et al, ASCO 2010; Fehninger et al, Blood 2011
57 Tosedostat depletes amino acid pool in neoplastic cells Selective depletion of AA in cancer cells Oral compound, well tolerated, first in class
58 Case study 58
59 Patient characteristics 78 yrs old male Date of diagnosis: November 2010 Presentation: dyspnea, weakness for 2 weeks Performance status: ECOG PS 2 Medical history: ischaemic heart disease with 2 stents hypertension 59
60 Lab findings PB counts: Hb 8.1 g/dl WBC 2.3 x 10 9 /L ANC 1.2 x 10 9 /L Platelets 63 x 10 9 /L BM aspirate Blasts 41 % Karyotyping complex: -5,-7,+8 Classification FAB: AML WHO: AML 60
61 How would you treat this patient? Standard induction chemotherapy Supportive care only Low dose chemotherapy: hydroxyurea or low dose AraC Azacitidine Decitabine Other Treatment decision: randomisation in AZA- AML-001: azacitidine 75 mg/m2 SC for 7 days every 28 days 61
62 Treatment outcome Treatment started on 30/11/2010 Best response : PR achieved between cycles 5-6 Response duration: PR maintained for 24 months ECOG PS: improved from 2 to 1 between cycles 3-4 Transfusion independence achieved at cycle 4 Gradual loss of response from 24 th cycle AZA stopped in April 2013 after 28 cycles Died in June 2013 with pneumonia 62
63 63
64 Cure is cool, but survival also 64
Meet-the-Expert: AML Treating older patients with AML
Meet-the-Expert: AML Treating older patients with AML Sergio Amadori Tor Vergata University Hospital Rome Istanbul 2012 AML in older patients Poor prognosis Minority treated with intensive Cx Treatment
More informationManagement of low and high risk MDS
Management of low and high risk MDS D.Selleslag AZ Sint-Jan Brugge, Belgium Brussels, 4th October 2014 Low / int 1 risk MDS Improve QOL Improve cytopenia Int 2 / high risk MDS Delay progression To AML
More informationAML IN OLDER PATIENTS Whenever possible, intensive induction therapy should be considered
AML IN OLDER PATIENTS Whenever possible, intensive induction therapy should be considered Charles A. Schiffer, M.D. Karmanos Cancer Institute Wayne State University School of Medicine Detroit, MI WHY ARE
More informationTreating Higher-Risk MDS. Case presentation. Defining higher risk MDS. IPSS WHO IPSS: WPSS MD Anderson PSS
Treating Higher-Risk MDS Eyal Attar, M.D. Massachusetts General Hospital Cancer Center eattar@partners.org 617-724-1124 Case presentation 72 year old man, prior acoustic neuroma WBC (X10 3 /ul) 11/08 12/08
More informationAcute Myeloid Leukemia
Acute Myeloid Leukemia Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University Outline Molecular biology Chemotherapy and Hypomethylating agent Novel Therapy
More informationASCO 2011: Leukemia. Disclosures
ASCO 2011: Leukemia E.J. Feldman M.D Weill-Cornell Medical College Disclosures Speaker does not report any affiliations 1 V617F JAK2 mutation in MPDs JAK STAT PATHWAY Signal transducers and activators
More informationTreatment of Low-Blast Count AML. Maria Teresa Voso Dipartimento di Biomedicina e Prevenzione Università di Roma Tor Vergata
Treatment of Low-Blast Count AML Maria Teresa Voso Dipartimento di Biomedicina e Prevenzione Università di Roma Tor Vergata Definition of Low-Blast Count AML Blast counts 20-30%, or > 10%? v Retrospective
More informationDisrupting the Cell Cycle to Treat AML and MDS Rodman & Renshaw Conference
CYC 682 Disrupting the Cell Cycle to Treat AML and MDS Rodman & Renshaw Conference September 2014 Disclaimer This presentation contains forward-looking statements within the meaning of the safe harbor
More informationDr Kavita Raj Consultant Haematologist Guys and St Thomas Hospital
Dr Kavita Raj Consultant Haematologist Guys and St Thomas Hospital IPSS scoring system Blood counts Bone marrow blast percentage Cytogenetics Age as a modulator of median survival IPSS Group Median Survival
More informationFirst Clinical Trial Day: Update on AML and CML trials. Barbara De Moerloose Brussels, June 20 th 2014
First Clinical Trial Day: Update on AML and CML trials Barbara De Moerloose Brussels, June 20 th 2014 Update on CML trials I-CML-Ped Study StopImaPed Study Nilotinib Phase 2 Study Guidelines for the management
More informationDepartment of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas; 2 Sunesis Pharmaceuticals, Inc, South San Francisco
Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) Naval Daver 1, Hagop Kantarjian 1, Guillermo
More informationLAM 20-30% Cristina Papayannidis, MD, PhD DIMES, Istituto di Ematologia L. e A. Seràgnoli Università di Bologna
LAM 20-30% Cristina Papayannidis, MD, PhD DIMES, Istituto di Ematologia L. e A. Seràgnoli Università di Bologna FAB CLASSIFICATION OF MYELODYSPLASTIC SYNDROME Subtype % Blood Myeloblasts Bone Marrow Myeloblasts
More informationAcute Myeloid Leukemia: State of the Art in 2018
Acute Myeloid Leukemia: State of the Art in 2018 Harry P. Erba, MD, PhD Professor, Department of Medicine Director, Leukemia Program Duke University Durham, NC Treatment Paradigm of Adults with AML Fit
More informationNational Horizon Scanning Centre. Decitabine (Dacogen) for myelodysplastic syndrome. April 2008
Decitabine (Dacogen) for myelodysplastic syndrome April 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be
More information39% Treated. 61% Untreated. 33% UnRx. 45% UnRx. 59% UnRx. 80% UnRx
AML in the Elderly สน น ว ส ทธ ศ กด ช ย งานประช มว ชาการกลางป สมาคมโลห ตว ทยาแห งประเทศไทย คร งท 53 25-26 ต ลาคม 2561 ณ โรงแรมเลอ เมอร เด ยน เช ยงใหม จ งหว ดเช ยงใหม 33% UnRx 45% UnRx 59% UnRx 80% UnRx
More informationNew concepts in the management of elderly patients with AML
New concepts in the management of elderly patients with AML Martha L. Arellano, MD Associate Professor of Hematology/Oncology Director, Hematology & Medical Oncology Fellowship Program Winship Cancer Institute
More informationRisk-adapted therapy of AML in younger adults. Sergio Amadori Tor Vergata University Hospital Rome
Risk-adapted therapy of AML in younger adults Sergio Amadori Tor Vergata University Hospital Rome Pescara 11/2010 AML: treatment outcome Age CR % ED % DFS % OS %
More information[ NASDAQ: MEIP ] Analyst & Investor Event December 8, 2014
[ NASDAQ: MEIP ] Analyst & Investor Event December 8, 2014 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events or results may
More informationLeucemia Mieloide Acuta Terapie Innovative. Adriano Venditti Ematologia Universita Tor Vergata, Roma
Leucemia Mieloide Acuta Terapie Innovative Adriano Venditti Ematologia Universita Tor Vergata, Roma Leucemia Mieloide Acuta Terapie Innovative Adriano Venditti Ematologia Universita Tor Vergata, Roma AML.Current
More informationRemission induction in acute myeloid leukemia
Int J Hematol (2012) 96:164 170 DOI 10.1007/s12185-012-1121-y PROGRESS IN HEMATOLOGY How to improve the outcome of adult acute myeloid leukemia? Remission induction in acute myeloid leukemia Eytan M. Stein
More information2 Workshop Nazionale SIES Ematologia Traslazionale Nuovi Farmaci e Strategie Terapeutiche nelle LMA
2 Workshop Nazionale SIES Ematologia Traslazionale Nuovi Farmaci e Strategie Terapeutiche nelle LMA Adriano Venditti Ematologia Universita Tor Vergata, Roma Current Treatment Results in AML AGE, y CR%
More informationScottish Medicines Consortium
Scottish Medicines Consortium azacitidine 100mg powder for suspension for injection (Vidaza ) No. (589/09) Celgene Ltd 05 March 2010 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationBackground CPX-351. Lancet J, et al. J Clin Oncol. 2017;35(suppl): Abstract 7035.
Overall Survival (OS) With Versus in Older Adults With Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia (taml): Subgroup Analysis of a Phase 3 Study Abstract 7035 Lancet JE, Rizzieri D, Schiller
More informationMyelodysplastic Syndromes. Post-ASH meeting 2014 Marie-Christiane Vekemans
Myelodysplastic Syndromes Post-ASH meeting 2014 Marie-Christiane Vekemans Agenda New biological developments Risk assessment and prognostic factors New therapeutic options Agenda New biological developments
More informationDepartment of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas; 2 Sunesis Pharmaceuticals, Inc, South San Francisco
Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) Naval Daver 1, Hagop Kantarjian 1, Guillermo
More informationKevin Kelly, MD, Phd Acute Myeloid and Lymphoid Leukemias
Kevin Kelly, MD, Phd Acute Myeloid and Lymphoid Leukemias Relevant financial relationships in the past twelve months by presenter or spouse/partner. Speakers bureau: Novartis, Janssen, Gilead, Bayer The
More informationSummary of Key AML Abstracts Presented at the European Hematology Association (EHA) June 22-25, 2017 Madrid, Spain
Summary of Key AML Abstracts Presented at the European Hematology Association (EHA) June 22-25, 2017 Madrid, Spain EHA 2017 ANNUAL MEETING: ABSTRACT SEARCH PAGE: https://learningcenter.ehaweb.org/eha/#!*listing=3*browseby=2*sortby=1*media=3*ce_id=1181*label=15531
More informationAcute Myeloid Leukemia Progress at last
Acute Myeloid Leukemia Progress at last Bruno C. Medeiros, MD September 9, 217 Introduction Mechanisms of leukemogenesis Emerging therapies in AML Previously untreated AML Relapsed and refractory patients
More informationAIH, Marseille 30/09/06
ALLOGENEIC STEM CELL TRANSPLANTATION FOR MYELOID MALIGNANCIES Transplant and Cellular Therapy Unit Institut Paoli Calmettes Inserm U599 Université de la Méditerranée ée Marseille, France AIH, Marseille
More informationPersonalized Therapy for Acute Myeloid Leukemia. Patrick Stiff MD Loyola University Medical Center
Personalized Therapy for Acute Myeloid Leukemia Patrick Stiff MD Loyola University Medical Center 708-327-3216 Major groups of Mutations in AML Targets for AML: Is this Achievable? Chronic Myeloid Leukemia:
More informationIDH1 AND IDH2 MUTATIONS
Mutant Isocitrate Dehydrogenase (midh) Inhibitors, Enasidenib or Ivosidenib, in Combination with Azacitidine (AZA): Preliminary Results of a Phase 1b/2 Study in Patients with Newly Diagnosed Acute Myeloid
More informationCREDIT DESIGNATION STATEMENT
CME Information LEARNING OBJECTIVES Recall the dose-limiting toxicity and preliminary clinical response results with 14- and 21-day extended treatment schedules of daily oral azacitidine. Apply new research
More informationTREATMENT UPDATES IN ACUTE LEUKEMIA. Shannon McCurdy, MD University of Pennsylvania
TREATMENT UPDATES IN ACUTE LEUKEMIA Shannon McCurdy, MD University of Pennsylvania TIMELINE FOR FDA APPROVED AGENTS FOR AML Midostuarin Enasidenib Cytarabine + Daunorubicin (7+3) Gemtuzumab Ozogamicin
More informationA paradigm shift in the therapy of low blast count acute myeloid leukemia. Valeria Santini UF Ematologia, Università di Firenze
A paradigm shift in the therapy of low blast count acute myeloid leukemia Valeria Santini UF Ematologia, Università di Firenze Patients (%) AML is predominantly a disease of the elderly 40 69% of patients
More informationLow Risk MDS Scoring System. Prognosis in Low Risk MDS. LR-PSS Validation 9/19/2012
Advances in MDS What s on the Horizon Tapan M. Kadia, MD Department of Leukemia MD Anderson Cancer Center Outline Newer Prognostic Systems Hypomethylating agent failures Newer Treatment approaches Role
More informationLa lenalidomide: meccanismo d azione e risultati terapeutici. F. Ferrara
La lenalidomide: meccanismo d azione e risultati terapeutici F. Ferrara MDS: new treatment goals Emerging treatment options expected to facilitate shift from supportive care to active therapy in MDS New
More informationMDS FDA-approved Drugs
MDS: Current Thinking on the Disease, Diagnosis, and Treatment Mikkael A. Sekeres, MD, MS Associate Professor of Medicine Director, Leukemia Program Dept of Hematologic Oncology and Blood Disorders Taussig
More informationESTABLISHED AND EMERGING THERAPIES FOR ACUTE MYELOID LEUKAEMIA. Dr Rob Sellar UCL Cancer Institute, London, UK
ESTABLISHED AND EMERGING THERAPIES FOR ACUTE MYELOID LEUKAEMIA Dr Rob Sellar UCL Cancer Institute, London, UK OVERVIEW Main focus on patients fit for intensive treatment Biological and Clinical Heterogeneity
More informationSafety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naïve Patients Aged 65 Years With Acute Myeloid Leukemia
Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naïve Patients Aged 65 Years With Acute Myeloid Leukemia Abstract 102 Wei AH, Strickland SA, Roboz GJ, Hou J-Z, Fiedler W, Lin TL,
More informationDisclosure Slide. Research Support: Onconova Therapeutics, Celgene
Oral Rigosertib Combined with Azacitidine in Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS): Effects in Treatment Naïve and Relapsed- Refractory Patients Shyamala C. Navada,
More informationFrontline Induc.on Therapy in 2017 Alan K Burne+
Frontline Induc.on Therapy in 2017 Alan K Burne+ Ravenna, October 2017 Standard of Care Induc5on: 7+3 Ara-C / Daunorubicin Consolida5on: High Dose Ara-C (3g doses) Total of 4 courses. Myeloabla5ve allogral
More informationEmerging Treatment Options for Myelodysplastic Syndromes
Emerging Treatment Options for Myelodysplastic Syndromes James K. Mangan, MD, PhD Assistant Professor of Clinical Medicine Abramson Cancer Center, University of Pennsylvania Please note that some of the
More informationSupplementary Materials for
Supplementary Materials for A Clinical Trial for Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes Not Eligible for Standard Clinical Trials Table of Contents Content Page Supplementary
More informationNational Horizon Scanning Centre. Azacitidine (Vidaza) for myelodysplastic syndrome. September 2007
Azacitidine (Vidaza) for myelodysplastic syndrome September 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationOncology Highlights: Leukemia & Myelodysplastic Syndromes
Oncology Highlights: Leukemia & Myelodysplastic Syndromes Jorge Cortes, MD Department of Leukemia The University of Texas, M.D. Anderson Cancer Center Highlights of the Day Leukemia & MDS AML: The field
More informationMaintaining Long-Term Efficacy in the Elderly MDS Patient with Poor Performance Status
Hi, my name is Dr. Hetty Carraway. I am a staff physician at the Taussig Cancer Institute at the Cleveland Clinic. Welcome to Managing MDS. 1 As you all are aware, many of our patients with MDS are in
More informationIPSS Modified 7/27/2011. WHO-Based Prognostic Scoring System (WPSS)
Advances in MDS Treatment: What s on the Horizon? New Prognostic Models and Therapies Jason Gotlib, MD, MS Assistant Professor of Medicine (Hematology) Stanford Cancer Center AA&MDSIF July 3, 011 WHO-Based
More informationTHE LEUKEMIAS. Etiology:
The Leukemias THE LEUKEMIAS Definition 1: malignant transformation of the pluripotent stem cell, successive expansion of the malignant clone from the bone marrow to the tissues Definition 2: Heterogenous
More informationAcute Myeloid Leukemia
Acute Myeloid Leukemia Guido Marcucci, M.D. Director, Gehr Family Center for Leukemia Research Hematologic Malignancies and Stem Cell Transplantation Institute City of Hope Acute Myeloid Leukemia Gene
More informationObjectives. I do not have anything to disclose.
Treatment of APL Objectives I do not have anything to disclose. Objectives 1. Urgency of early recognition and treatment 2. Treatment based on risk stratification 3. Monitoring for relapse 4. Treatment
More informationInotuzumab Ozogamicin in ALL. Hagop Kantarjian M.D. May 2016 Bologna, Italy
Inotuzumab Ozogamicin in ALL Hagop Kantarjian M.D. May 2016 Bologna, Italy Immuno Oncology in ALL Monoclonals + cytotoxic agents e.g.inotuzumab Bispecific monoclonals (CD3 + CD19) e.g.blinatumomab Modified
More informationSystemic Treatment of Acute Myeloid Leukemia (AML)
Guideline 12-9 REQUIRES UPDATING A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Systemic Treatment of Acute Myeloid Leukemia (AML) Members of the Acute Leukemia
More informationHow the Treatment of Acute Myeloid Leukemia is Changing in 2019
How the Treatment of Acute Myeloid Leukemia is Changing in 2019 Guido Marcucci, M.D. Director, Gehr Family Center for Leukemia Research Chair, Dept. Hematologic Malignancies Translational Science City
More informationEnhancing Survival Outcomes in the Management of Patients With Higher-Risk Myelodysplastic Syndromes
The classification, diagnosis, treatment goals, clinical experience, guidelines, and therapeutic options for higher-risk MDS patients are reviewed. Anne Silber. Ha Long Bay, Vietnam (detail). Limited edition
More informationNovel Induction and Targeted Strategies in Acute Myeloid Leukemia
Novel Induction and Targeted Strategies in Acute Myeloid Leukemia Eytan M. Stein, MD Leukemia Service Memorial Sloan Kettering Cancer Center Weill Cornell Medical College New York, New York Current Paradigms
More informationWednesday, November 30, 2011 University of Michigan
Wednesday, November 30, 2011 University of Michigan Presenter Gary J. Schiller, MD, FACP Professor, Department of Medicine, Hematology/Oncology Director, Hematological Malignancies/Stem Cell Transplantation
More informationNew treatment strategies in myelodysplastic syndromes and acute myeloid leukemia van der Helm, Lidia Henrieke
University of Groningen New treatment strategies in myelodysplastic syndromes and acute myeloid leukemia van der Helm, Lidia Henrieke IMPORTANT NOTE: You are advised to consult the publisher's version
More informationN Engl J Med Volume 373(12): September 17, 2015
Review Article Acute Myeloid Leukemia Hartmut Döhner, M.D., Daniel J. Weisdorf, M.D., and Clara D. Bloomfield, M.D. N Engl J Med Volume 373(12):1136-1152 September 17, 2015 Acute Myeloid Leukemia Most
More informationMolecularly Targeted Therapies - Strategies of the AMLSG
Molecularly Targeted Therapies - Strategies of the AMLSG Richard Schlenk Department of Internal Medicine III Ulm University, Germany Genotype-adapted Leukemia Program NAPOLEON GIMEMA/AMLSG/SAL APL [t(15;17)]
More informationUnderstanding & Treating Myelodysplastic Syndrome (MDS)
Understanding & Treating Myelodysplastic Syndrome (MDS) Casey O Connell, MD Associate Professor of Clinical Medicine Jane Anne Nohl Division of Hematology Keck School of Medicine of USC Let s Look at Our
More informationCLINICAL STUDY REPORT SYNOPSIS
CLINICAL STUDY REPORT SYNOPSIS Document No.: EDMS-PSDB-5412862:2.0 Research & Development, L.L.C. Protocol No.: R115777-AML-301 Title of Study: A Randomized Study of Tipifarnib Versus Best Supportive Care
More informationLA LEUCEMIA SECONDARIA: QUALI OPZIONI TERAPEUTICHE. Livio Pagano Istituto di Ematologia Università Cattolica S. Cuore Roma
LA LEUCEMIA SECONDARIA: QUALI OPZIONI TERAPEUTICHE Livio Pagano Istituto di Ematologia Università Cattolica S. Cuore Roma saml: Incidence In USA, NCI / SEER data - 1998 10,600 new patients with AML / year
More informationTreatment of APL. M a tth e w M e i, M.D. A s s is ta n t P ro fe s s o r C ity o f H o p e C o m p re h e n s iv e C a n c e r C e n te r
Treatment of APL M a tth e w M e i, M.D. A s s is ta n t P ro fe s s o r C ity o f H o p e C o m p re h e n s iv e C a n c e r C e n te r Disclosures I have nothing to disclose Objectives 1. Urgency of
More informationNeue zielgerichtete Behandlungsoptionen der neu diagnostizierten FLT3-positiven Akuten Myeloischen Leukämie (AML)
Neue zielgerichtete Behandlungsoptionen der neu diagnostizierten FLT3-positiven Akuten Myeloischen Leukämie (AML) Prof. Hartmut Döhner Klinik für Innere Medizin III, Universitätsklinikum Ulm Midostaurin
More informationEmerging Treatment Options for Myelodysplastic Syndromes
Emerging Treatment Options for Myelodysplastic Syndromes James K. Mangan, MD, PhD Assistant Professor of Clinical Medicine Abramson Cancer Center, University of Pennsylvania Please note that some of the
More informationEmerging Treatment Options for Myelodysplastic Syndromes
Emerging Treatment Options for Myelodysplastic Syndromes James K. Mangan, MD, PhD Assistant Professor of Clinical Medicine Abramson Cancer Center, University of Pennsylvania Please note that some of the
More informationBest of ASH: Acute leukemia. Frédéric Baron
Best of ASH: Acute leukemia Frédéric Baron I Acute Myeloid Leukemia Flt3 inhibitors (ratify, sorafenib after HCT) 5 other important abstracts (in brief) Mutated genes in AML FLT3: The Cancer Genome Atlas
More informationJ Clin Oncol 28: by American Society of Clinical Oncology INTRODUCTION
VOLUME 28 NUMBER 4 FEBRUARY 1 2010 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast
More informationIII. AML IN OLDER ADULTS: ARE WE LISTENING?
III. AML IN OLDER ADULTS: ARE WE LISTENING? Mikkael A. Sekeres, MD, MS* AML is a disease of older adults. In the US, the median age is 68 years and the age-adjusted population incidence is 17.6 per 100,000
More informationIndication for unrelated allo-sct in 1st CR AML
Indication for unrelated allo-sct in 1st CR AML It is time to say! Decision of allo-sct: factors to be considered Cytogenetic risk status Molecular genetics FLT3; NPM1, CEBPA. Response to induction Refractoriness
More informationEvolving Targeted Management of Acute Myeloid Leukemia
Evolving Targeted Management of Acute Myeloid Leukemia Jessica Altman, MD Robert H. Lurie Comprehensive Cancer Center of Northwestern University Learning Objectives Identify which mutations should be assessed
More informationStem cell transplantation for patients with AML in Republic of Macedonia: - 15 years of experience -
Stem cell transplantation for patients with AML in Republic of Macedonia: - 15 years of experience - R E S E A R C H A S S O C I A T E P R O F. D - R Z L A T E S T O J A N O S K I Definition Acute myeloid
More informationProgress in the treatment of acute promyelocytic leukemia. Lionel Adès, MD PhD Hopital Saint Louis, Paris Diderot University
Progress in the treatment of acute promyelocytic leukemia Lionel Adès, MD PhD Hopital Saint Louis, Paris Diderot University 대한혈액학회 Korean Society of Hematology COI disclosure Name of author : Lionel Adès
More informationReference: NHS England 1602
Clinical Commissioning Policy Proposition: Clofarabine for refractory or relapsed acute myeloid leukaemia (AML) as a bridge to stem cell transplantation Reference: NHS England 1602 First published: TBC
More informationShould patients with higher risk MDS (or AML in «early relapse») proceed directly to allo SCT without prior chemotherapy?
Should patients with higher risk MDS (or AML in «early relapse») proceed directly to allo SCT without prior chemotherapy? Pierre Fenaux Cohem 2012 Barcelona Should patients with higher risk MDS (or AML
More informationANCO Hematological Malignancies Update: The year in review. Midostaurin Vyxeos Gemtuzumab ozogamicin Enasidenib. The year in preview
ANCO Hematological Malignancies Update: Gabriel Mannis, MD Assistant Professor, and Marrow Co-Director, Cancer Immunotherapy Clinic Acute Leukemia Sacramento, CA June 16, 2018 OVERVIEW Overview The year
More informationLet s Look at Our Blood
Let s Look at Our Blood Casey O Connell, MD Associate Professor of Clinical Medicine Jane Anne Nohl Division of Hematology Keck School of Medicine of USC 10,000,000,000 WBCs/day Bone Marrow: The Blood
More informationASCO 2009 Leukemia MDS -Transplant
ASCO 2009 Leukemia MDS -Transplant Ruben A. Mesa, MD Professor of Medicine Mayo Clinic College of Medicine Scottsdale, AZ, USA mesa.ruben@mayo.edu American Society of Hematology State-of-the-Art Symposium
More informationPhiladelphia-positive Acute Lymphoblastic Leukemia
Philadelphia-positive Acute Lymphoblastic Leukemia Nicolas Boissel Service d Hématologie Unité Adolescents et Jeunes Adultes Hôpital Saint-Louis, Paris Ph+ acute lymphoblastic leukemia DR+, CD19+, CD22+,
More information2/10/2017. Updates in Acute Leukemia Therapy Blood Cancer Incidence in the United States, Leukemia Incidence in the Unites States, 2016
Updates in Acute Leukemia Therapy 2017 Aaron Logan, MD, PhD UCSF Division of Malignant Hematology and Blood and Marrow Transplantation aaron.logan@ucsf.edu @hemedoc Blood Cancer Incidence in the United
More informationOral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study
Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study Hagop Kantarjian, University of Texas MD Anderson Cancer Center Stefan Faderl, University
More informationAll patients with FLT3 mutant AML should receive midostaurin-based induction therapy. Not so fast!
All patients with FLT3 mutant AML should receive midostaurin-based induction therapy Not so fast! Harry P. Erba, M.D., Ph.D. Professor, Internal Medicine Director, Hematologic Malignancy Program University
More informationNew treatment strategies in myelodysplastic syndromes and acute myeloid leukemia van der Helm, Lidia Henrieke
University of Groningen New treatment strategies in myelodysplastic syndromes and acute myeloid leukemia van der Helm, Lidia Henrieke IMPORTANT NOTE: You are advised to consult the publisher's version
More informationTransfusion independence and survival in patients with acute myeloid leukemia treated with 5-azacytidine
Published Ahead of Print on August 8, 2012, as doi:10.3324/haematol.2012.065151. Copyright 2012 Ferrata Storti Foundation. Early Release Paper Transfusion independence and survival in patients with acute
More information5/21/2018. Disclosures. Objectives. Normal blood cells production. Bone marrow failure syndromes. Story of DNA
AML: Understanding your diagnosis and current and emerging treatments Nothing to disclose. Disclosures Mohammad Abu Zaid, MD Assistant Professor of Medicine Indiana University School of Medicine Indiana
More informationChemotherapeutic treatment of acute myeloid leukemia: incorporating the results of recent clinical trials
d Chemotherapeutic treatment of acute myeloid leukemia: incorporating the results of recent clinical trials Better outcomes for patients with acute myeloid leukemia over the last 30 years have been largely
More informationA Phase II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndromes (MDS)
A Phase II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndromes (MDS) Shyamala C. Navada, MD 1, Lewis R. Silverman, MD 1, Katherine Hearn, RN 2, Rosalie
More informationThe Changing Face of MDS: Advances in Treatment
Thank you very much again for listening to me. We are going to be talking now in terms of therapy of MDS or The Changing Face of MDS Advances in Treatment. My name is Guillermo Garcia-Manero. I am a Professor
More informationANCO 2015: Treatment advances in acute leukemia
ANCO 2015: Treatment advances in acute leukemia Michaela Liedtke, MD Stanford, CA September 12, 2015!" Disclosures Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Steering Committee
More informationThe Evolving Treatment Landscape in AML
The Evolving Treatment Landscape in AML Elias Jabbour, MD Associate Professor Section Chief, Acute Lymphocytic Leukemia Department of Leukemia Division of Cancer Medicine The University of Texas MD Anderson
More informationADVANCES IN THE MANAGEMENT OF MYELODYSPLASTIC SYNDROMES
ADVANCES IN THE MANAGEMENT OF MYELODYSPLASTIC SYNDROMES Corey Cutler, MD MPH FRCPC Associate Professor of Medicine, Harvard Medical School Dana-Farber Cancer Institute, Boston, MA HCT Outcomes - MDS 2001-2011
More informationThe combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia
Fredly et al. Clinical Epigenetics 2013, 5:13 RESEARCH Open Access The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia
More informationConcomitant WT1 mutations predicted poor prognosis in CEBPA double-mutated acute myeloid leukemia
Concomitant WT1 mutations predicted poor prognosis in CEBPA double-mutated acute myeloid leukemia Feng-Ming Tien, Hsin-An Hou, Jih-Luh Tang, Yuan-Yeh Kuo, Chien-Yuan Chen, Cheng-Hong Tsai, Ming Yao, Chi-Cheng
More informationBendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma
Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma Kahl BS et al. Cancer 2010;116(1):106-14. Introduction > Bendamustine is a novel alkylating
More informationUpdates in the Management of Acute Myeloid Leukemia
Updates in the Management of Acute Myeloid Leukemia Lydia Benitez, harmd, BCO 2017 TOA Conference I have no conflicts of interest with relation to the content of this presentation 4 Objectives Describe
More informationUnderstanding AML Casey O Connell, MD Associate Professor, Jane Anne Nohl Division of Hematology Keck School of Medicine, USC
First Let s Look at Our Blood Understanding AML Casey O Connell, MD Associate Professor, Jane Anne Nohl Division of Hematology Keck School of Medicine, USC Bone Marrow: The Blood Cell Factory 10,000,000,000
More informationMDS overview 전남대학교김여경
MDS overview 전남대학교김여경 2008 WHO Classification of MDS Name Abbreviation Key Feature Pts, % Refractory cytopenia, with unlineage, dysplasia Refractory anemia with ring sideroblasts RA Anemia and erythroid
More informationDisclosure. Study was sponsored by Karyopharm Therapeutics No financial relationships to disclose Other disclosures:
Combination of Selinexor with High-Dose Cytarabine and Mitoxantrone for Remission Induction in Acute Myeloid Leukemia is Feasible and Tolerable A Phase I Study (NCT02573363) Amy Y. Wang, Howie Weiner,
More informationENASIDENIB IN MUTANT-IDH2 RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML): RESULTS OF A PHASE 1 DOSE- ESCALATION AND EXPANSION STUDY
ENASIDENIB IN MUTANT-IDH2 RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML): RESULTS OF A PHASE 1 DOSE- ESCALATION AND EXPANSION STUDY Eytan M. Stein, Courtney D. DiNardo, Daniel A. Pollyea, Amir
More information